Author:
Chalkias Spyros,Harper Charles,Vrbicky Keith,Walsh Stephen R.,Essink Brandon,Brosz Adam,McGhee Nichole,Tomassini Joanne E.,Chen Xing,Chang Ying,Sutherland Andrea,Montefiori David C.,Girard Bethany,Edwards Darin K.,Feng Jing,Zhou Honghong,Baden Lindsey R.,Miller Jacqueline M.,Das Rituparna
Abstract
ABSTRACTBackgroundUpdated vaccination strategies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern are needed. Interim results of the safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster candidate are presented.MethodsIn this ongoing, phase 2/3 trial, the 50-μg bivalent vaccine mRNA-1273.214 (25-μg each ancestral Wuhan-Hu-1 and omicron B.1.1.529 spike SARS-CoV-2 mRNAs) was compared to the authorized 50-μg mRNA-1273 booster in adults who previously received 2-dose primary series of 100-μg mRNA-1273 and a first booster dose of 50-μg mRNA-1273 at least 3 months prior. Primary objectives were safety and reactogenicity, and immunogenicity of 50-μg mRNA-1273.214 compared with 50-μg mRNA-1273. Immunogenicity data 28 days after the booster dose are presented.ResultsFour hundred thirty-seven and 377 participants received 50-μg of mRNA-1273.214, or mRNA-1273, respectively. Median time between first and second booster doses of mRNA-1273.214 and mRNA-1273 were similar (136 and 134 days, respectively). In participants with no prior SARS-CoV-2 infection, observed omicron neutralizing antibody geometric mean titers (GMTs [95% confidence interval]) after the mRNA-1273.214 and mRNA-1273 booster doses, were 2372.4 (2070.6−2718.2) and 1473.5 (1270.8−1708.4) respectively and the model-based GMT ratio (97.5% confidence interval) was 1.75 (1.49−2.04). All pre-specified non-inferiority (ancestral SARS-CoV-2 with D614G mutation [D614G] GMT ratio; ancestral SARS-CoV-2 [D614G] and omicron seroresponse rates difference) and superiority primary objectives (omicron GMT ratio) for mRNA-1273.214 compared to mRNA-1273 were met. Additionally, mRNA-1273.214 50-μg induced a potent neutralizing antibody response against omicron subvariants BA.4/BA.5 and higher binding antibody responses against alpha, beta, gamma, delta and omicron variants. Safety and reactogenicity profiles were similar and well-tolerated for both vaccines groups.ConclusionThe bivalent vaccine mRNA-1273.214 50-μg was well-tolerated and elicited a superior neutralizing antibody response against omicron, compared to mRNA-1273 50-μg, and a non-inferior neutralizing antibody response against the ancestral SARS-CoV-2 (D614G), 28 days after immunization, creating a new tool as we respond to emerging SARS-CoV-2 variants.
Publisher
Cold Spring Harbor Laboratory
Reference29 articles.
1. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase;N Engl J Med,2021
2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
3. Cao Y , Yisimayi A , Jian F , et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. bioRxiv 2022. (Accessed June 24, 2022, at https://doi.org/10.1101/2022.04.30.489997
4. CoVariants. Overview of Variants in Countries. 2022. (Accessed June 24, 2022, at https://covariants.org/per-country.)
5. CoVariants. Overview of Variants/Mutations. 2022. (Accessed June 24, 2022, at https://covariants.org/variants.)
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献